Potential role of interferons in treating COVID-19 patients

被引:79
作者
Abdolvahab, Mohadeseh Haji [1 ]
Moradi-kalbolandi, Shima [1 ]
Zarei, Mohammad [2 ,3 ]
Bose, Deepanwita [4 ,5 ]
Majidzadeh-A, Keivan [1 ]
Farahmand, Leila [1 ]
机构
[1] ACECR, Motamed Canc Inst, Breast Canc Res Ctr, Recombinant Prot Dept, Tehran 1517964311, Iran
[2] Childrens Hosp Philadelphia, Ctr Mitochondrial & Epigen Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA USA
[5] Harvard Med Sch, Boston, MA 02115 USA
关键词
SARS-CoV-2; COVID-19; Respiratory Coronavirus; Pneumonia; Interferon; ACUTE-RESPIRATORY-SYNDROME; INNATE IMMUNE-RESPONSES; MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY; SYNDROME CORONAVIRUS; SYNERGISTICALLY INHIBIT; LOPINAVIR-RITONAVIR; ANTIVIRAL RESPONSE; SYNDROME SARS; I INTERFERON;
D O I
10.1016/j.intimp.2020.107171
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recently public health crises in the world is emerged by spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also named COVID-19. The virus is originated in bats and transported to humans via undefined intermediate animals. This virus can produce from weak to severe respiratory diseases including acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), pneumonia and even death in patients. The COVID-19 disease is distributed by inhalation via contaminated droplets or contact with infected environment. The incubation time is from 2 to 14 day and the symptoms are typically fever, sore throat, cough, malaise, fatigue, breathlessness among others. It needs to be considered that many infected people are asymptomatic. Developing various immunological and virological methods to diagnose this disease is supported by several laboratories. Treatment is principally supportive; however, there are several agents that are using in treating of COVID-19 patients. Interferons (IFNs) have shown to be crucial in fighting with COVID-19 disease and can be a suitable candidate in treatment of these patients. Combination therapy can be more effective than monotherapy to cure this disease. Prevention necessitates to be performed by isolation of suspected people and home quarantine as well as taking care to infected people with mild or strict disease at hospitals. As the outbreak of SARS-CoV-2 has accelerated, developing effective therapy is an urgent requirement to battle the virus and prevent further pandemic. In this manuscript we reviewed available information about SARS-CoV-2 and probable therapies for COVID-19 patients.
引用
收藏
页数:15
相关论文
共 160 条
[1]   Sacubitril/valsartan in COVID-19 patients: the need for trials [J].
Acanfora, Domenico ;
Ciccone, Marco Matteo ;
Scicchitano, Pietro ;
Acanfora, Chiara ;
Casucci, Gerardo .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (04) :253-254
[2]  
Agrawal Umang, 2020, Med J Armed Forces India, V76, P370, DOI 10.1016/j.mjafi.2020.08.004
[3]  
Ai T, 2020, RADIOLOGY, DOI [10.5772/intechopen.80730, DOI 10.1148/radiol.2020200642, 10.1148/radiol.202020064224, DOI 10.1148/RADIOL.2020200642, 10.1148/radiol.2020200642]
[4]   Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J].
Al-Tawfiq, Jaffar A. ;
Momattin, Hisham ;
Dib, Jean ;
Memish, Ziad A. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 20 :42-46
[5]  
American Library Association, 2020, COVID 19 COR PAND
[6]   COVID-19: lambda interferon against viral load and hyperinflammation [J].
Andreakos, Evangelos ;
Tsiodras, Sotirios .
EMBO MOLECULAR MEDICINE, 2020, 12 (06)
[7]  
Andrew King Elliot Lefkowitz Michael J., 2011, VIRUS TAXONOMY, V1st
[8]  
[Anonymous], EUR HEART J
[9]   Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial [J].
Arabi, Yaseen M. ;
Alothman, Adel ;
Balkhy, Hanan H. ;
Al-Dawood, Abdulaziz ;
AlJohani, Sameera ;
Al Harbi, Shmeylan ;
Kojan, Suleiman ;
Al Jeraisy, Majed ;
Deeb, Ahmad M. ;
Assiri, Abdullah M. ;
Al-Hameed, Fahad ;
AlSaedi, Asim ;
Mandourah, Yasser ;
Almekhlafi, Ghaleb A. ;
Sherbeeni, Nisreen Murad ;
Elzein, Fatehi Elnour ;
Memon, Javed ;
Taha, Yusri ;
Almotairi, Abdullah ;
Maghrabi, Khalid A. ;
Qushmaq, Ismael ;
Al Bshabshe, Ali ;
Kharaba, Ayman ;
Shalhoub, Sarah ;
Jose, Jesna ;
Fowler, Robert A. ;
Hayden, Frederick G. ;
Hussein, Mohamed A. .
TRIALS, 2018, 19
[10]  
Ataei M., 2020, MOL MECH GALIDESIVIR, P2